English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA cost-effectiveness analysis for the updated COVID-19 vaccine prepared for the CDC’s vaccine panel shows cost savings from vaccinating people over age 65, and good value from vaccinating adults of all ages.
Tag: Cost Effectiveness
Study finds genetic screening of adults would be cost-effective
An exhaustive cost-benefit analysis of population genetic testing published in Annals of Internal Medicine concludes with a recommendation to U.S. health policymakers to adopt routine testing of adults ages 40 and under for three genetic conditions posing high risk of life-threatening illness.
Helping transit agencies visualize the transition to electric bus fleets
The transit industry is rapidly moving toward battery electric bus fleets because of the environmental and financial benefits they offer.
Research provides valuable comparison of anticoagulant drugs
Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.
Randomized trial finds therapies for spine pain improved disability and quality of life but did not decrease healthcare spending
Pain in the back or the neck is extremely common and accounts for more healthcare spending than any other health condition.
How many free hot drinks and biscuits are excessive?
When free hot drinks and biscuits are on offer to healthcare staff, how much is reasonable to take before it’s deemed “excessive” consumption, ask researchers in the Christmas issue of The BMJ?
SGLT2 inhibitors and GLP1 receptor antagonists improve type-2 diabetes outcomes, but are not cost effective
A cost-effectiveness study of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists has found that the use of these medications as first-line treatment for type-2 diabetes would improve outcomes, but their costs would need to decrease by at least 70 percent to be cost-effective. The study is published in Annals of Internal Medicine.
New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.